Jonas Bergh

17PUBLICATIONS
138CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Apr 08, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.

Alexios Matikas, Evangelos Tzoras, Michail Sarafidis

|Jul 02, 2025
CYP2D6 genotype and outcome in tamoxifen treated early breast cancer.

Linda Thorén, Jonatan D Lindh, Espen Molden

|Mar 07, 2025
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

Ioannis Zerdes, Alexios Matikas, Artur Mezheyeuski

|Sep 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick

|Jul 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Alexios Matikas, Volker Möbus, Richard Greil

|Jun 28, 2024
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.

Caroline Boman, Xingrong Liu, Louise Eriksson Bergman

Pageof 3

Frequent Collaborators

7 joint publications

Theodoros Foukakis

7 joint publications

Alexios Matikas

5 joint publications

Ioannis Zerdes

4 joint publications

Balazs Acs